Submitted by Anonymous (not verified) on 3 August 2026 - 15:56
Human medicines European public assessment report (EPAR): Lytenava, bevacizumab, Date of authorisation: 27/05/2024, Revision: 6, Status: Authorised
Source:
Human medicines European public assessment report (EPAR): Lytenava, bevacizumab, Date of authorisation: 27/05/2024, Revision: 6, Status: Authorised